MannKind (MNKD)
(Delayed Data from NSDQ)
$5.11 USD
+0.25 (5.14%)
Updated Jun 21, 2024 04:00 PM ET
After-Market: $5.09 -0.02 (-0.39%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum B VGM
Brokerage Reports
0 items in cart
MannKind Corporation [MNKD]
Reports for Purchase
Showing records 101 - 120 ( 228 total )
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Recent Drug Launch Weekly Retail Sales Tracker - Week Ended March 6
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Discontinuation of Coverage of the Biotech Sector
Provider: Brinson Patrick Securities Corporation
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
2Q''14 Update; Model Changes from SNY Deal
Provider: Brinson Patrick Securities Corporation
Analyst: JAMES C
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Global Sanofi Deal: Finds Ideal Strategic Partner
Provider: Brinson Patrick Securities Corporation
Analyst: JAMES C
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
A Giant Leap - FDA approves Afrezza for type 1 and type 2 diabetes
Provider: Griffin Securities, Inc.
Analyst: MARKEY K
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Raising Price Target to $15.00 on FDA approval of Afrezza
Provider: Brinson Patrick Securities Corporation
Analyst: JAMES C
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
1Q''14 Update: Eagerly Anticipating Afrezza Approval.
Provider: Brinson Patrick Securities Corporation
Analyst: JAMES C
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
1Q''14 Update: Eagerly Anticipating Afrezza Approval
Provider: Brinson Patrick Securities Corporation
Analyst: JAMES C